MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7326/m20-0202

Медицинская библиотека · Annals of internal medicine · 2021

The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.

Bureau Christophe, Thabut Dominique, Jezequel Caroline, Archambeaud Isabelle, D'Alteroche Louis, Dharancy Sêbastien, Borentain Patrick, Oberti Frédéric, Plessier Aurélie, De Ledinghen Victor, Ganne-Carrié Nathalie, Carbonell Nicolas, Rousseau Vanessa, Sommet Agnès, Péron Jean Marie, Vinel Jean Pierre

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not been established.

OBJECTIVE

To determine whether rifaximin prevents overt HE after TIPS compared with placebo.

DESIGN

Randomized, double-blind, multicenter, placebo-controlled trial. (ClinicalTrials.gov: NCT02016196).

PARTICIPANTS

197 patients with cirrhosis undergoing TIPS for intractable ascites or prevention of variceal rebleeding.

INTERVENTION: Patients were randomly assigned to receive rifaximin (600 mg twice daily) or placebo, beginning 14 days before TIPS and continuing for 168 days after the procedure.

MEASUREMENTS: The primary efficacy end point was incidence of overt HE within 168 days after the TIPS procedure.

RESULTS

An episode of overt HE occurred in 34% (95% CI, 25% to 44%) of patients in the rifaximin group (n = 93) and 53% (CI, 43% to 63%) in the placebo group (n = 93) during the postprocedure period (odds ratio, 0.48 [CI, 0.27 to 0.87]). Neither the incidence of adverse events nor transplant-free survival was significantly different between the 2 groups.

LIMITATIONS: The study's conclusion applies mainly to patients with alcoholic cirrhosis, who made up the study population. The potential benefit of rifaximin 6 months after TIPS and beyond remains to be investigated.

CONCLUSION

In patients with cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. Rifaximin should therefore be considered for prophylaxis of post-TIPS HE.

PRIMARY FUNDING SOURCE: French Public Health Ministry.

Для цитирования: Bureau Christophe, Thabut Dominique, Jezequel Caroline, Archambeaud Isabelle, D'Alteroche Louis, Dharancy Sêbastien, Borentain Patrick, Oberti Frédéric, Plessier Aurélie, De Ledinghen Victor, Ganne-Carrié Nathalie, Carbonell Nicolas, Rousseau Vanessa, Sommet Agnès, Péron Jean Marie, Vinel Jean Pierre. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.. Annals of internal medicine. 2021. DOI: 10.7326/m20-0202.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.